Literature DB >> 12275504

Long-term administration of norethindrone in fertility control.

E Rice-wray, M Schulz-contreras, I Guerrero, A Aranda-rosell.   

Abstract

Entities:  

Keywords:  Acceptor Characteristics; Central America; Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Effectiveness; Contraceptive Methods--side effects; Contraceptive Usage; Demographic Factors; Dropouts; Endometrial Effects; Evaluation; Family Planning; Latin America; Longterm Effects; Low Income Population; Method Acceptability; Mexico; Norethindrone--administraction and dosage; Norethindrone--side effects; Oral Contraceptives--side effects; Parity; Population; Population Dynamics; Research Methodology; Reversibility; Sex Behavior; Time Factors; Use-effectiveness

Mesh:

Substances:

Year:  1962        PMID: 12275504

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  LIVER FUNCTION AFTER LONG-TERM PROGESTATIONAL TREATMENT WITH AND WITHOUT OESTROGEN.

Authors:  G LINTHORST
Journal:  Br Med J       Date:  1964-10-10

Review 2.  Mood and behavioral changes associated with the use of the oral contraceptive agents. A review of the literature.

Authors:  I D Glick
Journal:  Psychopharmacologia       Date:  1967

3.  Clinical trial of a combination of lynestrenol and mestranol (Lyndiol) as an oral contraceptive agent.

Authors:  E Rice-Wray; C Becerra; J Esquivel; M Maqueo
Journal:  Can Med Assoc J       Date:  1966-11-12       Impact factor: 8.262

4.  A new and practical oral contraceptive agent: norethindrone with mestranol.

Authors:  J H DICKINSON; G G SMITH
Journal:  Can Med Assoc J       Date:  1963-08-10       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.